Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

Nazar Farid(Eli Lilly (United States)), Daniel E. Salazar(Daiichi Sankyo (United States)), Kenneth J. Winters(Eli Lilly (United States)), John T. Brandt(Universitätsklinikum Würzburg), Joseph A. Jakubowski(Indiana Biosciences Research Institute), D. S. Small(Eli Lilly (United States)), Christelle Darstein(Novartis (Switzerland)), C. Steven Ernest(Metrum Research Group (United States)), Christopher D. Payne(Eli Lilly (United States))
Clinical Pharmacology & Therapeutics
March 14, 2007
10.1038/sj.clpt.6100139
Cited by 323

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
|American Heart Journal|2006|571
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
|European Heart Journal|2006|537